Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Int. braz. j. urol ; 47(1): 93-99, Jan.-Feb. 2021. tab, graf
Article in English | LILACS | ID: biblio-1134320


ABSTRACT Hypothesis: Endoclip can be used as fiducial marker in urology. Objective: To assess the feasibility, cost effectiveness and reliability of endoclips as novel fiducial markers in precision radiotherapy, as part of a trimodality bladder-preserving treatment (TBPT) of muscle-invasive bladder carcinoma. Materials and Methods: This retrospective study was performed at Weifang People's Hospital (Weifang, China) from January 2015 to June 2018. A total of 15 patients underwent TBPT. Endoclips were applied to healthy edges of the resected bladder wall as novel fiducial markers. Radio-sensitizing chemotherapy and routine precision radiotherapy were given. The number and position of the endoclips during radiotherapy sessions were monitored. Complications and tumor recurrence were analyzed. Results: The mean age (±standard deviation) of the patients was 67±10 years (range 46-79). There were 3 females and 12 males. Forty-nine endoclips were applied in all patients (3.3±0.8). The tumor was completely visibly resected in all patients. The number of endoclips remained the same through the planned last radiotherapy session (3.3±0.8), i.e., none were lost. All endoclips were removed after the last radiotherapy session. The average number of follow-up months was 38.9±13.2 (range 11-52). There were no procedure-related complications at discharge or follow-up. At one-year, overall recurrence-free survival was 93.3%. Two patients had recurrences at 18 months and 10 months after TBPT, respectively, and salvage radical cystectomy was performed with no further recurrences. Another patient died due to metastasis 9 months after the completion of therapy. Conclusions: Endoclips are reliable, safe and cost-effective as novel fiducial markers in precision-radiotherapy post-TBPT.

Humans , Male , Female , Aged , Urinary Bladder Neoplasms/surgery , Urinary Bladder Neoplasms/radiotherapy , Carcinoma , Urinary Bladder , Cystectomy , China , Feasibility Studies , Reproducibility of Results , Retrospective Studies , Treatment Outcome , Combined Modality Therapy , Fiducial Markers , Middle Aged , Muscles , Neoplasm Invasiveness , Neoplasm Recurrence, Local
Pakistan Journal of Pharmaceutical Sciences. 2015; 28 (3): 871-874
in English | IMEMR | ID: emr-191707


To find the novel hypolipidemic agents, the effects of ursolic acid and artesunate on hyperlipidemia were determined in rats fed a Western-type diet developed a hyperlipidemia. Rats received ursolic acid [50 mg/kg] or artesunate [50 mg/kg] alone, or in combination [25+25 mg/kg and 50+50 mg/kg], to prevent hyperlipidemia. Ursolic acid or artesunate alone significantly decreased the plasma triglyceride, but had no effect on the levels of cholesterol. The combination of ursolic acid and artesunate can reduce both triglyceride and cholesterol, and the effects were more potent than either agent alone, which indicates a strong synergistic effect. The hypolipidemic effect of artesunate is firstly reported. Its combination with ursolic acid might have the potential to further develop for the treatment of hyperlipidemia.